Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Lymphoma

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 153 articles:
HTML format



Single Articles


    July 2021
  1. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Prof. Anton Hagenbeek 1948-2021: Father of MRD and Lymphoma Expert.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01310.
    PubMed    


  2. ZHANG Y, Wang Y, Liu Y, Tong C, et al
    Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Leukemia. 2021 Jul 16. pii: 10.1038/s41375-021-01345.
    PubMed     Abstract available


  3. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
    Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
    Leukemia. 2021 Jul 9. pii: 10.1038/s41375-021-01311.
    PubMed     Abstract available


  4. PRITCHETT JC, Yang ZZ, Kim HJ, Villasboas JC, et al
    High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL).
    Leukemia. 2021 Jul 6. pii: 10.1038/s41375-021-01321.
    PubMed     Abstract available


    June 2021
  5. GRAHAM CE, Jozwik A, Quartey-Papafio R, Ioannou N, et al
    Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
    Leukemia. 2021 Jun 18. pii: 10.1038/s41375-021-01324.
    PubMed    


  6. JACHIMOWICZ RD, Klapper W, Glehr G, Muller H, et al
    Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
    Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01314.
    PubMed    


    May 2021
  7. LITTLE MP, Wakeford R, Zablotska LB, Borrego D, et al
    Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.
    Leukemia. 2021 May 28. pii: 10.1038/s41375-021-01284.
    PubMed     Abstract available


  8. WU F, Watanabe N, Tzioni MM, Akarca A, et al
    Thyroid MALT lymphoma: self-harm to gain potential T-cell help.
    Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01289.
    PubMed     Abstract available


  9. HE MY, Kridel R
    Treatment resistance in diffuse large B-cell lymphoma.
    Leukemia. 2021 May 20. pii: 10.1038/s41375-021-01285.
    PubMed     Abstract available


  10. GOLDMAN S, Barth M, Shiramizu B, Shi Q, et al
    A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
    Leukemia. 2021 May 3. pii: 10.1038/s41375-021-01256.
    PubMed    


    April 2021
  11. CHIHARA D, Miljkovic M, Iyer SP, Vega F, et al
    Targeted based therapy in nodal T-cell lymphomas.
    Leukemia. 2021;35:956-967.
    PubMed     Abstract available


    March 2021
  12. VALERO JG, Matas-Cespedes A, Arenas F, Rodriguez V, et al
    The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01201.
    PubMed     Abstract available


  13. LIM JQ, Huang D, Tang T, Tan D, et al
    Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
    Leukemia. 2021 Mar 8. pii: 10.1038/s41375-021-01195.
    PubMed    


  14. WENIGER MA, Kuppers R
    Molecular biology of Hodgkin lymphoma.
    Leukemia. 2021 Mar 8. pii: 10.1038/s41375-021-01204.
    PubMed     Abstract available


  15. MERRYMAN RW, Castagna L, Giordano L, Ho VT, et al
    Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
    Leukemia. 2021 Mar 3. pii: 10.1038/s41375-021-01193.
    PubMed     Abstract available


  16. FISKUS W, Mill CP, Perera D, Birdwell C, et al
    BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
    Leukemia. 2021 Mar 2. pii: 10.1038/s41375-021-01181.
    PubMed     Abstract available


  17. REUKEN PA, Stallmach A, Pletz MW, Brandt C, et al
    Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection.
    Leukemia. 2021;35:920-923.
    PubMed    


  18. ARMAND P, Lesokhin A, Borrello I, Timmerman J, et al
    A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
    Leukemia. 2021;35:777-786.
    PubMed     Abstract available


    February 2021
  19. GOUVEIA MH, Otim I, Ogwang MD, Wang M, et al
    Author Correction to: Endemic Burkitt lymphoma in second-degree relatives in Northern Uganda: in-depth genome-wide analysis suggests clues about genetic susceptibility.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01140.
    PubMed    


  20. LI X, Daniyan AF, Lopez AV, Purdon TJ, et al
    Cytokine IL-36gamma improves CAR T-cell functionality and induces endogenous antitumor response.
    Leukemia. 2021;35:506-521.
    PubMed     Abstract available


  21. HARTERT KT, Wenzl K, Krull JE, Manske M, et al
    Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
    Leukemia. 2021;35:522-533.
    PubMed     Abstract available


    January 2021
  22. VISCO C, Di Rocco A, Evangelista A, Quaglia FM, et al
    Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
    Leukemia. 2021 Jan 22. pii: 10.1038/s41375-020-01119.
    PubMed    


    December 2020
  23. MORSCHHAUSER F, Dyer MJS, Walter HS, Danilov AV, et al
    Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
    Leukemia. 2020 Dec 17. pii: 10.1038/s41375-020-01108.
    PubMed    


  24. MOMBLED M, Rodriguez L, Avalon M, Duchez P, et al
    Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
    Leukemia. 2020;34:3370-3381.
    PubMed     Abstract available


  25. VEAZEY KJ, Cheng D, Lin K, Villarreal OD, et al
    CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
    Leukemia. 2020;34:3269-3285.
    PubMed     Abstract available


    November 2020
  26. LOBELLO C, Tichy B, Bystry V, Radova L, et al
    STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
    Leukemia. 2020 Nov 27. pii: 10.1038/s41375-020-01093.
    PubMed    


  27. WANG H, Wei W, Zhang JP, Song Z, et al
    A novel model of alternative NF-kappaB pathway activation in anaplastic large cell lymphoma.
    Leukemia. 2020 Nov 12. pii: 10.1038/s41375-020-01088.
    PubMed     Abstract available


  28. YANG C, Xie M, Zhang K, Liu H, et al
    Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
    Leukemia. 2020;34:3055-3059.
    PubMed    


  29. LIBERT D, Yuan CM, Masih KE, Galera P, et al
    Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
    Leukemia. 2020;34:3064-3069.
    PubMed    


    October 2020
  30. ZENT CS, Brady MT, Delage C, Strawderman M, et al
    Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Leukemia. 2020 Oct 30. pii: 10.1038/s41375-020-01074.
    PubMed    


  31. GOUVEIA MH, Otim I, Ogwang MD, Mingyi W, et al
    Endemic Burkitt Lymphoma in second-degree relatives in Northern Uganda: in-depth genome-wide analysis suggests clues about genetic susceptibility.
    Leukemia. 2020 Oct 13. pii: 10.1038/s41375-020-01052.
    PubMed    


  32. DINNESSEN MAW, van der Poel MWM, Tonino SH, Visser O, et al
    Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.
    Leukemia. 2020 Oct 12. pii: 10.1038/s41375-020-01048.
    PubMed     Abstract available


  33. WANG L, Wang JW
    PD-1 blockade in extranodal NK/T-cell lymphoma: who is in charge?
    Leukemia. 2020 Oct 2. pii: 10.1038/s41375-020-01046.
    PubMed    


  34. WANG Y, Liu Y, Tan X, Pan B, et al
    Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.
    Leukemia. 2020;34:2704-2707.
    PubMed     Abstract available


  35. BALINAS-GAVIRA C, Rodriguez MI, Andrades A, Cuadros M, et al
    Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL.
    Leukemia. 2020;34:2722-2735.
    PubMed     Abstract available


    September 2020
  36. YANG Y, Wang Y, Liu X, He X, et al
    Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
    Leukemia. 2020 Sep 17. pii: 10.1038/s41375-020-01042.
    PubMed     Abstract available


  37. KURODA Y, Yashima-Abo A, Koyama D, Kikuchi J, et al
    Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.
    Leukemia. 2020 Sep 14. pii: 10.1038/s41375-020-01035.
    PubMed    


  38. JUNCO JJ, Chen T, Rashid R, Terrell M, et al
    An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.
    Leukemia. 2020 Sep 11. pii: 10.1038/s41375-020-01036.
    PubMed    


    August 2020
  39. NIE K, Redmond D, Eng KW, Zhang T, et al
    Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma.
    Leukemia. 2020 Aug 12. pii: 10.1038/s41375-020-01014.
    PubMed    


  40. VISCO C, Di Rocco A, Evangelista A, Quaglia FM, et al
    Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
    Leukemia. 2020 Aug 11. pii: 10.1038/s41375-020-01013.
    PubMed     Abstract available


  41. LIM JQ, Huang D, Tang T, Tan D, et al
    Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
    Leukemia. 2020 Aug 5. pii: 10.1038/s41375-020-1000.
    PubMed    


  42. BURKE GAA, Beishuizen A, Bhojwani D, Burkhardt B, et al
    Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
    Leukemia. 2020;34:2271-2275.
    PubMed    


    July 2020
  43. CHIBA S, Sakata-Yanagimoto M
    Advances in understanding of angioimmunoblastic T-cell lymphoma.
    Leukemia. 2020 Jul 23. pii: 10.1038/s41375-020-0990.
    PubMed     Abstract available


  44. PRUTSCH N, Gurnhofer E, Suske T, Liang HC, et al
    Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Leukemia. 2020 Jul 14. pii: 10.1038/s41375-020-0968.
    PubMed     Abstract available


  45. GUAN P, Dong T, Zhang L, Zhao S, et al
    Staging challenges in extranasal and juvenile extranodal NK/T-cell lymphoma.
    Leukemia. 2020 Jul 14. pii: 10.1038/s41375-020-0975.
    PubMed    


  46. ZHU J, Yang Y, Tao J, Wang SL, et al
    Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.
    Leukemia. 2020 Jul 10. pii: 10.1038/s41375-020-0963.
    PubMed     Abstract available


    June 2020
  47. LANTERMANS HC, Minderman M, Kuil A, Kersten MJ, et al
    Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0934.
    PubMed     Abstract available


  48. MARCAIS A, Lhermitte L, Artesi M, Laurent C, et al
    Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype.
    Leukemia. 2020 Jun 17. pii: 10.1038/s41375-020-0900.
    PubMed     Abstract available


    May 2020
  49. DRIESSEN J, Visser O, Zijlstra JM, Lugtenburg PJ, et al
    Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 May 28. pii: 10.1038/s41375-020-0875.
    PubMed     Abstract available


  50. REUTTER K, Sandmann S, Rohde J, Muller S, et al
    Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma.
    Leukemia. 2020 May 14. pii: 10.1038/s41375-020-0862.
    PubMed    


  51. YOUNG KH
    Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0861.
    PubMed    


  52. ATTARBASCHI A, Carraro E, Ronceray L, Andres M, et al
    Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0841.
    PubMed     Abstract available


  53. WULF GG, Altmann B, Ziepert M, D'Amore F, et al
    Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
    Leukemia. 2020 May 7. pii: 10.1038/s41375-020-0838.
    PubMed     Abstract available


  54. CUCCO F, Barrans S, Sha C, Clipson A, et al
    Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
    Leukemia. 2020;34:1329-1341.
    PubMed     Abstract available


  55. HU G, Phillips JL, Dasari S, Jacobs HK, et al
    Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.
    Leukemia. 2020;34:1467-1471.
    PubMed    


  56. DUPLOYEZ N, Goursaud L, Fenwarth L, Bories C, et al
    Familial myeloid malignancies with germline TET2 mutation.
    Leukemia. 2020;34:1450-1453.
    PubMed    


    April 2020
  57. NAKAMURA K, Casey M, Oey H, Vari F, et al
    Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
    Leukemia. 2020 Apr 8. pii: 10.1038/s41375-020-0811.
    PubMed     Abstract available


    March 2020
  58. CHEN Q, Feng J, Wu J, Yu Z, et al
    HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression.
    Leukemia. 2020 Mar 23. pii: 10.1038/s41375-020-0801.
    PubMed     Abstract available


  59. HUSBY S, Favero F, Nielsen C, Sorensen BS, et al
    Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study.
    Leukemia. 2020 Mar 20. pii: 10.1038/s41375-020-0795.
    PubMed     Abstract available


  60. KREUTMAIR S, Klingeberg C, Poggio T, Andrieux G, et al
    Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0789.
    PubMed     Abstract available


  61. DI M, Ollila TA, Olszewski AJ
    Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0798.
    PubMed    


  62. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0797.
    PubMed     Abstract available


  63. CHEN SY, Yang Y, Qi SN, Wang Y, et al
    Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.
    Leukemia. 2020 Mar 9. pii: 10.1038/s41375-020-0791.
    PubMed     Abstract available


  64. FRAGLIASSO V, Verma A, Manzotti G, Tameni A, et al
    The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK(-) anaplastic large cell lymphoma by regulating the DNA helicase HELLS.
    Leukemia. 2020 Mar 2. pii: 10.1038/s41375-020-0754.
    PubMed     Abstract available


  65. HERBRUEGGEN H, Mueller S, Rohde J, Arias Padilla L, et al
    Treatment and outcome of IG-MYC(+) neoplasms with precursor B-cell phenotype in childhood and adolescence.
    Leukemia. 2020;34:942-946.
    PubMed    


    February 2020
  66. KAWASHIMA M, Carreras J, Higuchi H, Kotaki R, et al
    PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Leukemia. 2020 Feb 24. pii: 10.1038/s41375-020-0737.
    PubMed     Abstract available


  67. TIAN XP, Xie D, Huang WJ, Ma SY, et al
    A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.
    Leukemia. 2020 Feb 20. pii: 10.1038/s41375-020-0757.
    PubMed     Abstract available


  68. HONG H, Li Y, Lim ST, Liang C, et al
    A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group.
    Leukemia. 2020 Feb 17. pii: 10.1038/s41375-020-0740.
    PubMed    


  69. LENZ G, Hawkes E, Verhoef G, Haioun C, et al
    Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
    Leukemia. 2020 Feb 14. pii: 10.1038/s41375-020-0743.
    PubMed     Abstract available


  70. SONG JY, Egan C, Bouska AC, Zhang W, et al
    Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma.
    Leukemia. 2020 Feb 13. pii: 10.1038/s41375-020-0739.
    PubMed    


  71. GUO F, Luo Y, Jiang X, Lu X, et al
    Recent BCR stimulation induces a negative autoregulatory loop via FBXO10 mediated degradation of HGAL.
    Leukemia. 2020;34:553-566.
    PubMed     Abstract available


  72. POTT C, Sehn LH, Belada D, Gribben J, et al
    MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
    Leukemia. 2020;34:522-532.
    PubMed     Abstract available


    January 2020
  73. ZHANG X, Bi C, Lu T, Zhang W, et al
    Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
    Leukemia. 2020;34:138-150.
    PubMed     Abstract available


    December 2019
  74. PICHARD A, Marcatili S, Karam J, Constanzo J, et al
    The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest.
    Leukemia. 2019 Dec 13. pii: 10.1038/s41375-019-0677.
    PubMed     Abstract available


  75. RULE SA, Cartron G, Fegan C, Morschhauser F, et al
    Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
    Leukemia. 2019 Dec 11. pii: 10.1038/s41375-019-0658.
    PubMed    


    November 2019
  76. JIN X, Shi Q, Li Q, Zhou L, et al
    CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-kappaB signaling.
    Leukemia. 2019 Nov 27. pii: 10.1038/s41375-019-0661.
    PubMed     Abstract available


  77. RAVI D, Sarkar S, Purvey S, Passero F, et al
    Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
    Leukemia. 2019 Nov 26. pii: 10.1038/s41375-019-0663.
    PubMed     Abstract available


  78. HARRINGTON CT, Sotillo E, Robert A, Hayer KE, et al
    Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
    Leukemia. 2019 Nov 22. pii: 10.1038/s41375-019-0650.
    PubMed     Abstract available


  79. GEHRINGER F, Weissinger SE, Moller P, Wirth T, et al
    Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.
    Leukemia. 2019 Nov 12. pii: 10.1038/s41375-019-0628.
    PubMed     Abstract available


  80. KAMIJO H, Miyagaki T, Takahashi-Shishido N, Nakajima R, et al
    Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
    Leukemia. 2019 Nov 11. pii: 10.1038/s41375-019-0622.
    PubMed     Abstract available


  81. RIABINSKA A, Lehrmann D, Jachimowicz RD, Knittel G, et al
    ATM activity in T cells is critical for immune surveillance of lymphoma in vivo.
    Leukemia. 2019 Nov 5. pii: 10.1038/s41375-019-0618.
    PubMed     Abstract available


  82. MOHTY M, Gautier J, Malard F, Aljurf M, et al
    CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Leukemia. 2019 Nov 5. pii: 10.1038/s41375-019-0615.
    PubMed     Abstract available


    October 2019
  83. YOUNG KH
    Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?
    Leukemia. 2019 Oct 22. pii: 10.1038/s41375-019-0608.
    PubMed    


  84. ADAMS CM, Mitra R, Vogel AN, Liu J, et al
    Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma.
    Leukemia. 2019 Oct 21. pii: 10.1038/s41375-019-0611.
    PubMed    


  85. EICHENAUER DA, Plutschow A, Fuchs M, Hartmann S, et al
    Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group.
    Leukemia. 2019 Oct 21. pii: 10.1038/s41375-019-0609.
    PubMed    


  86. JIANG D, Tian X, Bian X, Zhu T, et al
    T cells redirected against Igbeta for the immunotherapy of B cell lymphoma.
    Leukemia. 2019 Oct 17. pii: 10.1038/s41375-019-0607.
    PubMed     Abstract available


    September 2019
  87. WANG M, Rule S, Zinzani PL, Goy A, et al
    Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
    Leukemia. 2019 Sep 26. pii: 10.1038/s41375-019-0575.
    PubMed    


  88. STAIGER AM, Altenbuchinger M, Ziepert M, Kohler C, et al
    A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
    Leukemia. 2019 Sep 17. pii: 10.1038/s41375-019-0573.
    PubMed     Abstract available


  89. SONG Y, Gao Q, Zhang H, Fan L, et al
    Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Leukemia. 2019 Sep 13. pii: 10.1038/s41375-019-0545.
    PubMed     Abstract available


  90. SCHEIJEN B, Meijers RWJ, Rijntjes J, van der Klift MY, et al
    Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS.
    Leukemia. 2019;33:2227-2240.
    PubMed     Abstract available


    August 2019
  91. DESCH AK, Hartung K, Botzen A, Brobeil A, et al
    Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.
    Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0541.
    PubMed     Abstract available


  92. SUN Y, Ding N, Song Y, Yang Z, et al
    Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
    Leukemia. 2019;33:2105-2110.
    PubMed    


  93. RACK KA, van den Berg E, Haferlach C, Beverloo HB, et al
    European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms.
    Leukemia. 2019;33:1851-1867.
    PubMed     Abstract available


    July 2019
  94. KATAOKA K, Miyoshi H, Sakata S, Dobashi A, et al
    Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Leukemia. 2019;33:1687-1699.
    PubMed     Abstract available


  95. LEE G, Ryu HJ, Choi JW, Kang H, et al
    Characteristic gene alterations in primary gastrointestinal T- and NK-cell lymphomas.
    Leukemia. 2019;33:1797-1832.
    PubMed    


    June 2019
  96. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.
    Leukemia. 2019 Jun 25. pii: 10.1038/s41375-019-0511.
    PubMed     Abstract available


  97. ALKODSI A, Cervera A, Zhang K, Louhimo R, et al
    Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.
    Leukemia. 2019 Jun 11. pii: 10.1038/s41375-019-0509.
    PubMed     Abstract available


    May 2019
  98. NAM J, Kim DU, Kim E, Kwak B, et al
    Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
    Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0492.
    PubMed     Abstract available


  99. ZHU F, Guo H, Bates PD, Zhang S, et al
    PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Leukemia. 2019 May 23. pii: 10.1038/s41375-019-0489.
    PubMed     Abstract available


  100. JAIN T, Sauter CS, Shah GL, Maloy MA, et al
    Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
    Leukemia. 2019 May 21. pii: 10.1038/s41375-019-0476.
    PubMed    


  101. LUPINO L, Perry T, Margielewska S, Hollows R, et al
    Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
    Leukemia. 2019 May 16. pii: 10.1038/s41375-019-0478.
    PubMed     Abstract available


  102. WATATANI Y, Sato Y, Miyoshi H, Sakamoto K, et al
    Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.
    Leukemia. 2019 May 15. pii: 10.1038/s41375-019-0473.
    PubMed     Abstract available


  103. STILGENBAUER S, Aurran Schleinitz T, Eichhorst B, Lang F, et al
    Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
    Leukemia. 2019 May 14. pii: 10.1038/s41375-019-0475.
    PubMed    


  104. CRISTOFOLETTI C, Bresin A, Picozza M, Picchio MC, et al
    Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.
    Leukemia. 2019;33:1231-1242.
    PubMed     Abstract available


  105. TORREY H, Khodadoust M, Tran L, Baum D, et al
    Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sezary syndrome.
    Leukemia. 2019;33:1206-1218.
    PubMed     Abstract available


    April 2019
  106. TIAN XP, Huang WJ, Huang HQ, Liu YH, et al
    Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.
    Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0466.
    PubMed     Abstract available


  107. PAPIN A, Tessoulin B, Bellanger C, Moreau A, et al
    CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0463.
    PubMed     Abstract available


    March 2019
  108. HARRINGTON CT, Sotillo E, Robert A, Hayer KE, et al
    Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
    Leukemia. 2019 Mar 26. pii: 10.1038/s41375-019-0454.
    PubMed     Abstract available


  109. ARAF S, Wang J, Korfi K, Pangault C, et al
    Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2019 Mar 23. pii: 10.1038/s41375-019-0425.
    PubMed     Abstract available


  110. SASI BK, Martines C, Xerxa E, Porro F, et al
    Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0442.
    PubMed     Abstract available


  111. NGUYEN PH, Niesen E, Hallek M
    New roles for B cell receptor associated kinases: when the B cell is not the target.
    Leukemia. 2019;33:576-587.
    PubMed     Abstract available


    January 2019
  112. VEKARIA PH, Kumar A, Subramaniam D, Dunavin N, et al
    Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
    Leukemia. 2019 Jan 21. pii: 10.1038/s41375-018-0355.
    PubMed     Abstract available


  113. DODERO A, Guidetti A, Tucci A, Barretta F, et al
    Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.
    Leukemia. 2019 Jan 10. pii: 10.1038/s41375-018-0320.
    PubMed    


  114. THURNER L, Hartmann S, Fadle N, Kemele M, et al
    LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
    Leukemia. 2019;33:148-158.
    PubMed     Abstract available


  115. ANASTASIADOU E, Stroopinsky D, Alimperti S, Jiao AL, et al
    Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Leukemia. 2019;33:132-147.
    PubMed     Abstract available


    December 2018
  116. EDGINTON-WHITE B, Cauchy P, Assi SA, Hartmann S, et al
    Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0311.
    PubMed     Abstract available


  117. PENG RJ, Han BW, Cai QQ, Zuo XY, et al
    Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0324.
    PubMed     Abstract available


    October 2018
  118. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Abstract available


  119. HOUOT R, Cartron G, Bijou F, de Guibert S, et al
    Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0282.
    PubMed    


    August 2018
  120. PRUTSCH N, Gurnhofer E, Suske T, Liang HC, et al
    Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0239.
    PubMed     Abstract available


  121. BORCHMANN S, Muller H, Haverkamp H, Baues C, et al
    Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG).
    Leukemia. 2018 Aug 21. pii: 10.1038/s41375-018-0240.
    PubMed     Abstract available


    April 2018
  122. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Abstract available


    March 2018
  123. SCHLEUSSNER N, Merkel O, Costanza M, Liang HC, et al
    The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
    Leukemia. 2018 Mar 28. pii: 10.1038/s41375-018-0045.
    PubMed     Abstract available


  124. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Abstract available


    February 2018
  125. GALLARDO F, Bertran J, Lopez-Arribillaga E, Gonzalez J, et al
    Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0066.
    PubMed     Abstract available


  126. ARAF S, Wang J, Korfi K, Pangault C, et al
    Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2018 Feb 8. pii: 10.1038/s41375-018-0043.
    PubMed    


  127. NAIRISMAGI M-, Gerritsen ME, Li ZM, Wijaya GC, et al
    Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0004.
    PubMed     Abstract available


  128. RULE S, Jurczak W, Jerkeman M, Rusconi C, et al
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0023.
    PubMed    


  129. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
    Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
    Leukemia. 2018;32:364-375.
    PubMed     Abstract available


  130. LIU E, Tong Y, Dotti G, Shaim H, et al
    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Leukemia. 2018;32:520-531.
    PubMed     Abstract available


    November 2017
  131. HARTMANN K, Illing A, Leithauser F, Baisantry A, et al
    Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice.
    Leukemia. 2017 Nov 10. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  132. GERMINI D, Tsfasman T, Klibi M, El-Amine R, et al
    HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.
    Leukemia. 2017;31:2515-2522.
    PubMed     Abstract available


    October 2017
  133. HU G, Dasari S, Asmann YW, Greipp PT, et al
    Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Oct 13. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  134. SOMMERMEYER D, Hill T, Shamah SM, Salter AI, et al
    Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Leukemia. 2017;31:2191-2199.
    PubMed     Abstract available


  135. CHEN KH, Wada M, Pinz KG, Liu H, et al
    Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Leukemia. 2017;31:2151-2160.
    PubMed     Abstract available


    September 2017
  136. JIA YJ, Liu ZB, Wang WG, Sun CB, et al
    HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
    Leukemia. 2017 Sep 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  137. VRZALIKOVA K, Ibrahim M, Vockerodt M, Perry T, et al
    S1PR1 drives a feed forward signalling loop to regulate BATF3 and the transcriptional programme of hodgkin lymphoma cells.
    Leukemia. 2017 Sep 7. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    August 2017
  138. FUJISAWA M, Sakata-Yanagimoto M, Nishizawa S, Komori D, et al
    Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.
    Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  139. ZAMO A, Pischimarov J, Schlesner M, Rosenstiel P, et al
    Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole exome sequencing.
    Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  140. KARUBE K, Enjuanes A, Dlouhy I, Jares P, et al
    Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    July 2017
  141. CHEADLE EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, et al
    A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  142. YAO Z, Deng L, Xu-Monette ZY, Manyam GC, et al
    Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  143. JAIN N, Zhu H, Khashab T, Ye Q, et al
    Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
    Leukemia. 2017 Jul 10. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    June 2017
  144. SUN B, Fiskus W, Qian Y, Rajapakshe K, et al
    BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  145. LOLLIES A, Hartmann S, Schneider M, Bracht T, et al
    An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
    Leukemia. 2017 Jun 29. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    May 2017
  146. KASENDA B, Ihorst G, Schroers R, Korfel A, et al
    High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma-a prospective multicentre trial by the German cooperative PCNSL study group.
    Leukemia. 2017 May 31. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    April 2017
  147. VAN DER MEULEN M, Dinmohamed AG, Visser O, Doorduijn JK, et al
    Improved survival in primary central nervous system lymphoma up to age 70 only: A population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.
    Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    March 2017
  148. ATSAVES V, Tsesmetzis N, Chioureas D, Kis L, et al
    PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
    Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
    PubMed     Abstract available


  149. DZIKIEWICZ-KRAWCZYK A, Kok K, Slezak-Prochazka I, Robertus JL, et al
    ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma.
    Leukemia. 2017 Mar 23. doi: 10.1038/leu.2017.
    PubMed     Abstract available


    January 2017
  150. MONJEZI R, Miskey C, Gogishvili T, Schleef M, et al
    Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Leukemia. 2017;31:186-194.
    PubMed     Abstract available


  151. RUELLA M, Kenderian SS, Shestova O, Klichinsky M, et al
    Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
    Leukemia. 2017;31:246-248.
    PubMed    


    March 2016
  152. GONDEK LP, Zheng G, Ghiaur G, DeZern AE, et al
    Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
    Leukemia. 2016 Mar 15. doi: 10.1038/leu.2016.
    PubMed     Abstract available


    February 2016
  153. MIRANDA MB, Lauseker M, Kraus MP, Proetel U, et al
    Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment- long-term observation in CML Study IV.
    Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: